FDA approves Retatrutide this year?

Prediction market · Polymarket

Overview

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Ticker

fda-approves-retatrutide-this-year

Volume

421.9K

24h volume

24.2K

1w volume

27.7K

Open interest

0

Liquidity

2.1K

Liquidity CLOB

2.1K

Start

Jan 12, 2026

End

Dec 31, 2026

Status

Active

Access

Restricted

Created

Jan 12, 2026

Event ID

158107

Slug

fda-approves-retatrutide-this-year

Markets

1

Tags

drug GLP Eli Lilly Science Chinese Peptides Tech FDA

Raw event data

{
  "id": "158107",
  "ticker": "fda-approves-retatrutide-this-year",
  "slug": "fda-approves-retatrutide-this-year",
  "title": "FDA approves Retatrutide this year?",
  "description": "Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nIf the listed drug is approved within this market’s timeframe, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.",
  "resolutionSource": "",
  "startDate": "2026-01-12T23:09:01.744068Z",
  "creationDate": "2026-01-12T23:09:01.744065Z",
  "endDate": "2026-12-31T00:00:00Z",
  "image": "https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg",
  "icon": "https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg",
  "active": true,
  "closed": false,
  "archived": false,
  "new": false,
  "featured": false,
  "restricted": true,
  "liquidity": 2100.5283,
  "volume": 421900.945531,
  "openInterest": 0,
  "createdAt": "2026-01-11T18:01:54.338474Z",
  "updatedAt": "2026-02-22T09:03:59.439656Z",
  "competitive": 0.9296920395119117,
  "volume24hr": 24211.194566000002,
  "volume1wk": 27691.985704000002,
  "volume1mo": 420442.81105299894,
  "volume1yr": 421885.94553099887,
  "enableOrderBook": true,
  "liquidityClob": 2100.5283,
  "commentCount": 2,
  "markets": [
    {
      "id": "1162139",
      "question": "FDA approves Retatrutide this year?",
      "conditionId": "0xa9e844555c3aeac59e6104f266bee4ce930b6941fbea4053eb1ab440cdc4ea8e",
      "slug": "fda-approves-retatrutide-this-year",
      "resolutionSource": "",
      "endDate": "2026-12-31T00:00:00Z",
      "liquidity": "2100.5283",
      "startDate": "2026-01-12T23:07:41.222409Z",
      "image": "https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg",
      "icon": "https://polymarket-upload.s3.us-east-2.amazonaws.com/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654-UwIlSPqRRYN3.jpg",
      "description": "Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.\n\nThis market will resolve to \"Yes\" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to \"No.\"\n\nAn approval is defined as:\nFor new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)\nFor already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced\nFor generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)\nFor biosimilars: FDA approval of a 351(k) application\n\nThe following constitute qualifying approvals:\nStandard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs\n\nThe following do not constitute qualifying approvals:\nApprovable letters that require additional actions before approval\nTentative approvals pending patent or exclusivity expiration\nFDA requests for additional information or studies\nExtension of Prescription Drug User Fee Amendments dates\nApproval for compassionate use or expanded access programs only\nApproval only for export or for use outside the United States\nEmergency Use Authorization (EUA) without full approval\nComplete Response Letters (CRLs) indicating the application cannot be approved in its current form\n\nIf the listed drug is approved within this market’s timeframe, the market will resolve to \"Yes,\" regardless of potential Advisory Committee votes against approval or later withdrawal of approval.\n\nConditional approvals may include post-marketing requirements or commitments and still qualify.\n\nThe primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.",
      "outcomes": "[\"Yes\", \"No\"]",
      "outcomePrices": "[\"0.225\", \"0.775\"]",
      "volume": "421900.945531",
      "active": true,
      "closed": false,
      "marketMakerAddress": "",
      "createdAt": "2026-01-11T18:01:55.248991Z",
      "updatedAt": "2026-02-22T09:03:20.859866Z",
      "new": false,
      "featured": false,
      "submitted_by": "0x91430CaD2d3975766499717fA0D66A78D814E5c5",
      "archived": false,
      "resolvedBy": "0x65070BE91477460D8A7AeEb94ef92fe056C2f2A7",
      "restricted": true,
      "groupItemTitle": "",
      "groupItemThreshold": "0",
      "questionID": "0x28ca6aea72aab17e940ef2cd33fe2b8b75be387cd6a6f8a5652f3789b121aa71",
      "enableOrderBook": true,
      "orderPriceMinTickSize": 0.01,
      "orderMinSize": 5,
      "volumeNum": 421900.945531,
      "liquidityNum": 2100.5283,
      "endDateIso": "2026-12-31",
      "startDateIso": "2026-01-12",
      "hasReviewedDates": true,
      "volume24hr": 24211.194566000002,
      "volume1wk": 27691.985704000002,
      "volume1mo": 420442.81105299894,
      "volume1yr": 421885.94553099887,
      "clobTokenIds": "[\"37046612607917670308080402239015003453544974634272162340833828461002861888000\", \"88804198326803208210051239842322035314858564707784139836567124873063625803223\"]",
      "umaBond": "500",
      "umaReward": "5",
      "volume24hrClob": 24211.194566000002,
      "volume1wkClob": 27691.985704000002,
      "volume1moClob": 420442.81105299894,
      "volume1yrClob": 421885.94553099887,
      "volumeClob": 421900.945531,
      "liquidityClob": 2100.5283,
      "customLiveness": 0,
      "acceptingOrders": true,
      "negRisk": false,
      "negRiskRequestID": "",
      "ready": false,
      "funded": false,
      "acceptingOrdersTimestamp": "2026-01-12T23:07:19Z",
      "cyom": false,
      "competitive": 0.9296920395119117,
      "pagerDutyNotificationEnabled": false,
      "approved": true,
      "clobRewards": [
        {
          "id": "55010",
          "conditionId": "0xa9e844555c3aeac59e6104f266bee4ce930b6941fbea4053eb1ab440cdc4ea8e",
          "assetAddress": "0x2791Bca1f2de4661ED88A30C99A7a9449Aa84174",
          "rewardsAmount": 0,
          "rewardsDailyRate": 2,
          "startDate": "2026-01-13",
          "endDate": "2500-12-31"
        }
      ],
      "rewardsMinSize": 20,
      "rewardsMaxSpread": 3.5,
      "spread": 0.01,
      "oneDayPriceChange": 0.015,
      "oneHourPriceChange": 0.005,
      "oneWeekPriceChange": 0.005,
      "oneMonthPriceChange": 0.09,
      "lastTradePrice": 0.22,
      "bestBid": 0.22,
      "bestAsk": 0.23,
      "automaticallyActive": true,
      "clearBookOnStart": true,
      "manualActivation": false,
      "negRiskOther": false,
      "umaResolutionStatuses": "[]",
      "pendingDeployment": false,
      "deploying": false,
      "deployingTimestamp": "2026-01-12T22:52:16.73248Z",
      "rfqEnabled": false,
      "holdingRewardsEnabled": false,
      "feesEnabled": false,
      "requiresTranslation": false,
      "feeType": null
    }
  ],
  "tags": [
    {
      "id": "101221",
      "label": "drug",
      "slug": "drug",
      "createdAt": "2024-11-11T18:32:53.640553Z",
      "updatedAt": "2026-02-06T20:03:11.687201Z",
      "requiresTranslation": false
    },
    {
      "id": "103116",
      "label": "GLP",
      "slug": "glp",
      "createdAt": "2026-01-11T18:01:54.734515Z",
      "updatedAt": "2026-02-06T19:58:13.311696Z",
      "requiresTranslation": false
    },
    {
      "id": "103118",
      "label": "Eli Lilly",
      "slug": "eli-lilly",
      "createdAt": "2026-01-11T18:01:54.897124Z",
      "updatedAt": "2026-02-06T20:03:51.921207Z",
      "requiresTranslation": false
    },
    {
      "id": "74",
      "label": "Science",
      "slug": "science",
      "forceShow": false,
      "publishedAt": "2023-11-02 21:16:20.623+00",
      "updatedBy": 13,
      "createdAt": "2023-11-02T21:16:20.826Z",
      "updatedAt": "2026-02-06T20:15:20.36977Z",
      "forceHide": true,
      "requiresTranslation": false
    },
    {
      "id": "103117",
      "label": "Chinese Peptides",
      "slug": "chinese-peptides",
      "createdAt": "2026-01-11T18:01:54.746493Z",
      "updatedAt": "2026-02-06T20:17:30.730561Z",
      "requiresTranslation": false
    },
    {
      "id": "1401",
      "label": "Tech",
      "slug": "tech",
      "forceShow": false,
      "publishedAt": "2024-02-21 23:06:12.305+00",
      "createdAt": "2024-02-21T23:06:12.324Z",
      "updatedAt": "2026-02-06T20:17:30.722289Z",
      "requiresTranslation": false
    },
    {
      "id": "101489",
      "label": "FDA",
      "slug": "fda",
      "createdAt": "2024-12-13T19:40:18.578389Z",
      "updatedAt": "2026-02-06T20:07:42.292472Z",
      "requiresTranslation": false
    }
  ],
  "cyom": false,
  "showAllOutcomes": true,
  "showMarketImages": true,
  "enableNegRisk": false,
  "automaticallyActive": true,
  "negRiskAugmented": false,
  "pendingDeployment": false,
  "deploying": false,
  "requiresTranslation": false
}

FDA approves Retatrutide this year?
Vol 421.9KLiq 2.1KEnd Dec 31, 2026OpenOrder book